…
[Read more...] about Current Company Presentation – Feb 2023
A Revolution in Treating Autoinflammatory & Orphan Diseases
Akari TX /
Akari TX /
• Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024 • …
Akari TX /
NEW YORK and LONDON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …